Generic Name: sacubitril/valsartan
Brand Name: Entresto
Manufacturer: Novartis Pharma Inc.
Indications: Heart failure, NYHA Class II or III
Manufacturer Requested Reimbursement Criteria1: Addition to the current criteria: Initiation of sacubitril/valsartan may be considered in patients stabilized from a heart failure hospitalization without prior exposure to angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB).
Submission Type: Resubmission
Project Status: Active
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | March 30, 2020 |
| Call for patient input closed | May 20, 2020 |
| Clarification: - Patient input submission received from The HeartLife Foundation | |
| Submission received | May 22, 2020 |
| Submission accepted | June 05, 2020 |
| Review initiated | June 08, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | September 02, 2020 |
| Deadline for sponsors comments | September 14, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | October 08, 2020 |
| Expert committee meeting (initial) | October 21, 2020 |
| Draft recommendation issued | November 02, 2020 To November 04, 2020 |